T ypical as well as atypical chest pain are common symptoms in patients with hypertrophic cardiomyopathy. Several pieces of evidence suggest the possibility of microvascular ischemia associated with these clinical symptoms. 'Tl imaging has revealed both reversible and irreversible perfusion defects,1-3 whereas invasive techniques have demonstrated increased myocardial lactate production as metabolic evidence of ischemia.4 In addition, tissue histology has revealed focal myocardial scarring5 and narrowing of intramural septal arteries. 6 However, little is known about the metabolic state and regional blood flow in myocardium of symptomatic patients with hypertrophic cardiomyopathy.
Studies from several institutions have indicated that regionally enhanced glucose uptake relative to blood flow is a sensitive index of myocardial ischemia.7-10 With high temporal resolution positron emission tomography (PET), both regional myocardial blood flow and glucose utilization can now be quantified noninvasively in humans. In contrast to a previous investigation from this laboratory on asymptomatic patients with hypertrophic cardiomyopathy,11 the purpose of this study was to assess quantitatively regional myocardial blood flow and potential alterations in regional glucose metabolism in patients with symptomatic hypertrophic cardiomyopathy, who are possibly a different clinical entity than asymptomatic patients. The underlying hypothesis was that such measurements might reveal metabolic evidence of regional myocardial ischemia in highly symptomatic patients.12-14 Methods 
Patient Population
Thirteen symptomatic patients were studied at rest with PET and intravenous N-13 ammonia and F-18 deoxyglucose. In addition, four of the patients were studied again during and immediately after symptomlimited supine bicycle exercise. Nine of the patients were men and four were women. Their age averaged 43±18 years, ranging from 20 to 69 years. All patients met clinical, echocardiographic, and angiographic criteria of hypertrophic cardiomyopathy such as a nondilated asymmetrically hypertrophied left ventricle and absence of other cardiac or systemic diseases causing left ventricular hypertrophy.1215 All patients had normal coronary angiograms within the preceding 3 months and none was known to suffer from a metabolic disorder or had a history of diabetes. The left ventricular ejection fraction averaged 73±9% (range, 55-80%) as determined by contrast ventriculography in 10 patients and by two-dimensional echocardiography in three patients. Three patients had a significant outflow tract gradient at rest and two with provocation by postextrasystolic potentiation. Ten patients received a daily dose of 240-720 mg verapamil, one patient was on 80 mg propranolol per day, and two did not take medication. Clinical symptoms ranged from moderate to severe exertional angina, typical chest pain, and palpitations to dyspnea of New York Heart Association grades II and III. Anginal episodes tended to be more frequent and severe in younger patients; three patients had a familial history of hypertrophic cardiomyopathy (Table 1) .
Tomographic Imaging Protocol
Each patient gave informed consent in writing after the investigative nature and possible risk of the study had been explained in detail. The study protocol and informed consent form had been approved by the Human Subject Protection Committee of the University of California, Los Angeles. Patients were requested to fast for at least 4 hours and to discontinue cardiac medications for at least 24 hours. An off-drug period of more than 5 half-times was achieved in all cases for both verapamil (T/2=4.0± 1.5 hours) and propranolol (T/2=3.9+0.4 hours) 16 ; most patients were off medication for 48 hours. Before PET, a 12-lead ECG, venous blood samples, sphygmomanometric blood pressure, and two-dimensional and M-mode echocardiograms were obtained in standard fashion. 13 The patients were then positioned supine in a wholebody tomograph (ECAT III, Computer Technology Inc., Knoxville, Tenn.), which acquires simultaneously three transaxial planes (two direct and one interpolated central cross plane).17 The planes were spaced 9 mm apart. The effective (reconstructed) in-plane resolution was 11.6 mm, and the axial resolution was :10 mm (full-width at half-maximum).17 Consistency in patient positioning was achieved by marking the chest with a felt pen and aligning the marks with the tomograph's low-energy neon laser beam.
After recording of transmission images for subsequent correction of photon attenuation (using an external gallium-68 ring source), positron emitting tracers were given as a single bolus under resting conditions. N-13 ammonia was administered first; serial images were recorded for 10 minutes starting with a standardized intravenous 30-second bolus of -10 mCi (370 MBq) of N-13 ammonia. '8,'9 The image acquisition sequence consisted of 12x10-second images, 4x30-second images, and one final 360-second image that served as a static image as well (17 serial images over 10 minutes).
While maintaining the patients in exactly the same position by aligning ink marks on the patient's chest with the laser beam of the scanner, 10 mCi (370 MBq) of F-18 deoxyglucose was administered intravenously.20,21 F-18 deoxyglucose was injected 35-40 minutes after N-13 ammonia over a 20-second period; serial images were acquired as follows: 12x 10-second images, 12x30-second images, lOx 120-second images, 6x300-second images, and, finally, acquisition of one 600-second image amounting to a total acquisition time of 67 minutes. The last set of three contiguous images served as static images that were compared with the corresponding static N-13 ammonia images.
To examine the effect of exercise stress on regional myocardial blood flow and glucose utilization, the imaging protocol was repeated in four patients 22±7 days after the resting study during symptom-limited supine bicycle exercise. A bicycle ergometer was mounted to the tomograph's bed to allow comfortable cycling while the patients were positioned supine in the tomograph and fixed by a shoulder support. The exercise started at a level of Table 2 ). Numbers in parentheses denote extent of MM in degrees on the circumference. fast while waiting for up to 2 hours before the PET study and to limit fluid intake to water only.
Analysis of Tomographic Images
A VAX 780 computer (DEC) was used for analysis of the serially acquired PET images, for the circumferential profile analysis, and for quantification of regional myocardial blood flow and glucose metabolism. eliminates effects of regional partial volume on count recovery because it is identical for both tracers and thus cancels out. Therefore, the circumferential profile activities were not corrected for regional variations in partial volume effect as a result of regional differences in left ventricular myocardial thickness.
Quantification of Regional Myocardial Blood Flow and Glucose Utilization
Regional time-activity curves. These were generated by placing elliptical regions of interest to hypertrophied septal and to nonhypertrophied myocardium (which served as a reference) as well as in the left ventricular cavity. The regions of interest were then copied to all serial images recorded after N-13 ammonia and after F-18 deoxyglucose administration. The average (rather than maximum) N-13 or F-18 activity counts derived from each region of interest on the serial images then were corrected for dead time and partial volume, and time-activity curves for myocardium and the left ventricular blood pool were obtained. Corrections for partial volume effects and, thus, for the underestimation of counts in normal walls, were based on echocardiographic measurements of regional wall thickness in both hypertrophied and nonhypertrophied myocardium. 25 The accuracy of measurements of the arterial tracer input function and of the regional myocardial tracer tissue concentrations was based on in vivo echocardiographic measurements of wall thickness validated previously in animal experiments and in studies with humans. 18, 21, 26 Regional myocardial blood flow. This was quantified with a two-compartment tracer kinetic model for N-13 ammonia including correction for spillover of activity from blood into myocardium. The model fit was applied to the initial 90 seconds of the myocardial time-activity curves and yielded estimates of regional myocardial Transaxial images of blood flow and glucose utilization in two patients are shown in Figure 1 . As indicated in Table 1 , myocardial blood flow was rather heterogeneous in most patients and, further, varied considerably between patients. For the group of 13 patients, blood flow averaged 0.99±0.13 mL * min'* g-' in nonhypertrophied myocardium; flow to the hypertrophied myocardium was significantly lower and averaged 0.78±0.19 mL* min'* g`(p<0.025). Ratios of blood flow in hypertrophied to nonhypertrophied myocardium ranged from 0.46 to 1.07 and thus reflected the considerable intra-and interindividual heterogeneity of myocardial blood flow. As this ratio averaged 0.79±0.20, blood flow was on average 21% lower in hypertrophied than in nonhypertrophied myocardium.
Compared with blood flow, the regional rates of glucose utilization were more homogeneous. Ratios between hypertrophied and nonhypertrophied myocardium ranged from 0.77 to 1.29 and averaged 1 . Blood flow in the septum was 0.6 mL*min'.g ' and 0.92 mL * minm * g-' in the free wall. A correction for count losses due to partial volume effects was performed for the left ventricular free wall based on echocardiographic measurements. Because the septal thickness was more than twice the resolution of the imaging system, usually no correction for partial volume losses was required for quantitative measurements in the septum. 17 micromoles of glucose per milliliter of blood. Because of lower blood flows, hypertrophied myocardium extracted significantly more glucose (1.19±0.47 ,umol/mL) than nonhypertrophied myocardium (0.80±0.35 gmol/mL, p<0.05). Circumferential profile analysis revealed in three of the 13 patients a blood flow-metabolism mismatch at rest.
Effect of Exercise
Four patients could be subjected to supine bicycle exercise during a second PET study ( Figure 2 . Circumferential profile analysis demonstrated in two of the four patients new blood flow metabolism mismatches after exercise that had not been present at rest. In a third patient, a mismatch observed already at rest increased in size after exercise. Blood flow during exercise averaged 0.91±0.10 mL* minm g in nonhypertrophied myocardium and thus did not significantly change from rest (1.01±0.11 mL* minm g-1). In hypertrophied segments, however, blood flow during exercise averaged only 0.57±0.33 mL minm g-1 compared with 0.75 ±0.23 mL * min-1 g-at rest; this difference failed to attain statistical significance. Nevertheless, myocardial blood flow became more heterogeneous with exercise; the ratio of blood flow in hypertrophied to nonhypertrophied myocardium averaged 0.74±0.18 at rest and 0.61±0.37 during exercise. Similarly, exercise led to increased regional differences in myocardial glucose utilization rates. Measurements of plasma substrate levels in three of the four patients subjected to exercise revealed no significant changes in glucose and fatty acid levels from rest to exercise but did reveal a physiological increase in plasma lactate levels (8.8±1.6 mg/dL at rest versus 27.5± 19.4 mg/dL during exercise, p<0.05).
Discussion
Evaluation of relative distributions as well as quantification of regional myocardial blood flow and exogenous glucose utilization with PET revealed an inhomogeneous pattern in symptomatic patients with hypertrophic cardiomyopathy. Despite this variability, blood flow for the whole group of 13 patients was significantly lower in hypertrophied than in nonhypertrophied myocardial regions, whereas rates of glucose utilization were similar. This disparity between blood flow and glucose metabolism resulted in a blood flow-metabolism mismatch at rest in three patients. With exercise, blood flow failed to increase in nonhypertrophied regions and fell slightly in hypertrophied myocardial regions. Therefore, two patients developed new blood flow-metabolism mismatches, and one patient with a mismatch at rest developed an enlarging mismatch with exercise. There were five different patients with mismatches (Tables 1 and 2 ).
The results of this study suggest the presence of "metabolic ischemia" in the hypertrophied myocardium of patients with hypertrophic cardiomyopathy and expand on findings with`0'Tl and '3N ammonia suggesting myocardial ischemia based on mere perfusion abnormalities32,33 or lactate production.34 In addition to metabolic evidence of ischemia in the hypertrophied segment, quantitative measurements revealed an abnormal flow response to physical stress not only confined to regions of hypertrophy but also in adjacent nonhypertrophied segments. Similar to results by Camici et al, 32 who reported resting blood flows of 0.90±0.35 and 1.14+0.43 mL * minm . g`in nonhypertrophied and hypertrophied myocardium, respectively, the current study revealed a resting flow of 0.99+0.13 and 0.78+0.19 mL* min'* g`in the free wall and the septum, respectively. In contrast to an attenuated increase in flow to 1.47+±0.58 mL -min'* g`after dipyridamole challenge as described by these authors, the current study did not demonstrate a significant augmentation of blood flow to nonhypertrophied and hypertrophied myocardium in response to symptom-limited exercise; a physiological exercise-induced augmentation of blood flow has been previously shown in normal subjects.28 In contrast to the vasodilating action of dipyridamole used by Camici et a132 to assess flow reserve, the current study used ergometric stress. Unlike pharmacological vasodilation, physical stress in these patients leads to an increase in left ventricular end-diastolic pressure, causing a further impairment of diastolic function35,36 and subendocardial perfusion and possibly a limited increase in cardiac output.37,38 In addition, intramyocardial "squeezing" forces may be more vigorous with physical stress and further obstruct blood flow.14 The concerted action of the tachycardia-related diminution in diastolic filling time, impaired muscle relaxation, and increased wall tension resulting from an elevated diastolic filling pressure with exercise may therefore have been responsible for the lack of increased flow during exercise.
Interestingly, wall thickness in hypertrophied segments with a blood flow-metabolism mismatch was in-plane image resolution of 11.6 mm), it is significant for nonhypertrophied myocardium. Correction for partial volume effect in this study was based on regional wall thickness measurement by M-mode echocardiography, which has been shown previously to correlate closely to wall thickness by magnetic resonance imaging.11 Therefore, by matching the tomograms with a corresponding echogram, care was taken to avoid misalignment between the sites of wall thickness measurements and the placement of regions of interest. Nevertheless, whereas such misalignments were avoided by two-dimensional echo orientation and M-mode measurements, slightly variable measurements may not be totally excluded but would be expected to be random rather than distributed unidirectionally.
Both resting and exercise blood flow measurements were quantified from the initial 90 seconds of the time-activity curves; however, the aggravation of angina or dyspnea precluded continuation of exercise beyond 60 seconds. Therefore, the obtained values of blood flow may have theoretically underestimated true flows during peak exercise. However, first, heart rate did not decline by >15% within the initial 30 seconds after stopping exercise, and second, >90% of ammonia becomes trapped within the first 60 seconds; therefore, a potential underestimation is likely to be negligible. This notion does not apply to the quantitative glucose studies because most of the metabolic trapping occurred after the initial 60 seconds; thus, the derived values for glucose metabolism mostly reflect conditions immediately after exercise. 45 Finally, the image quality after injection of F-18 deoxyglucose was usually good or excellent, and uptake was documented in all regions of the myocardium, indicating that all patients were imaged under fasted condition regardless of mildly elevated plasma glucose levels in two cases. Only one patient (No. 8) had inadequate uptake in the septum that precluded quantitation.
Clinical Implications
An augmentation in regional glucose utilization relative to regional perfusion is considered a sensitive index of regional myocardial ischemia. With the advent of quantitative assessment of both regional blood flow and glucose uptake, PET not only provides a sensitive and powerful tool to identify myocardial hypoperfusion under physiological conditions but also may elucidate the role of metabolic ischemia in hypertrophic cardiomyopathy. Different from the viability issue in coronary artery disease with mismatches as markers of viable tissue, in hypertrophic cardiomyopathy the emphasis is placed on the quantitative relation of a relatively increased glucose utilization rate and regional blood flow at rest or with physical stress in order to identify ischemia in this group of patients and to shed light on the pathomechanism of asymptomatic focal infarction as frequently seen on histological sections.539 Moreover, because therapeutic concepts for hypertrophic cardiomyopathy are mainly based on empiric and clinical judgment, the quantitative assessment of flow and metabolism could possibly elucidate effects of medical therapy and may also provide an effective way of therapy control.
Finally, regardless of the conflicting data on risk stratification in hypertrophic cardiomyopathy, evidence of myocardial ischemia may also have prognostic impact. 36, 46 Considering that 22% of persons dying from sudden unexpected death under the age of 40 years suffer from hypertrophic cardiomyopathy,47 it may be conceivable that within a heterogeneous spectrum of this disease, an extensive disarray of myocardial architecture implies focal ischemia and may serve as a nidus of ventricular arrhythmias predisposing to sudden death.46,48 Especially young patients with extensive hypertrophy and severe symptoms suggestive of ischemia are threatened by syncope and sudden death.37,47 Further prospective studies are needed relating the pattern of regional perfusion and metabolism to the individual clinical outcome in order to characterize a potential prognostic impact of metabolic abnormalities in hypertrophic cardiomyopathy.
